布拉氏酵母菌散联合美沙拉嗪肠溶片治疗轻中度溃疡性结肠炎的临床效果

Clinical efficacy of Saccharomyces boulardii sachets combined with mesalazine slow release tablets in the treatment of mild to moderate ulcerative colitis

目的探讨布拉氏酵母菌散联合美沙拉嗪肠溶片治疗轻中度溃疡性结肠炎的临床效果。方法选取2020年1月至2022年5月就诊于我院的64例轻中度溃疡性结肠炎患者,随机将其分为对照组和治疗组,每组32例。对照组给予美沙拉嗪肠溶片治疗,治疗组在此基础上加用布拉氏酵母菌散治疗。比较两组的治疗效果。结果治疗组的治疗总有效率明显高于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的Mayo评分比较,差异无统计学意义(P>0.05);治疗后,两组的Mayo评分均显著降低,且治疗组低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的红细胞沉降率(ESR)、C反应蛋白(CRP)水平比较,差异无统计学意义(P>0.05);治疗后,两组的ESR、CRP水平均显著降低,且治疗组低于对照组,差异具有统计学意义(P<0.05)。结论布拉氏酵母菌散联合美沙拉嗪肠溶片治疗轻中度溃疡性结肠炎的效果显著,可改善患者临床症状,减轻肠黏膜炎症,且无明显不良反应发生,值得推广应用。

Objective To investigate the clinical efficacy of Saccharomyces boulardii sachets combined with mesalazine slow release tablets in the treatment of mild to moderate ulcerative colitis.Methods Sixty-four patients with mild to moderate ulcerative colitis admitted in our hospital from January 2020 to May 2022 were selected and randomly divided into control group and treatment group,with 32 cases in each group.The control group was treated with mesalazine slow release tablets,and the treatment group was additionally treated with Saccharomyces boulardii sachets.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment of the treatment group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in Mayo score between the two groups(P>0.05);after treatment,the Mayo score of both groups significantly decreased,that in the treatment group was lower than the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in erythrocyte sedimentation rate(ESR)and C-reactive protein(CRP)level between the two groups(P>0.05);after treatment,ESR and CRP level in both groups significantly decreased,those in the treatment group were lower than the control group,and the differences were statistically significant(P<0.05).Conclusion The Saccharomyces boulardii sachets combined with mesalazine slow release tablets has remarkable effect on the treatment of mild to moderate ulcerative colitis,it can improve the clinical symptoms of patients,reduce intestinal mucosal inflammation,and no obvious adverse reactions,which is worthy of promotion and application.